Related Experiment Video
Updated: May 9, 2026
08:15
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Liver injury associated with antidepressants
1Titus Family Department of Clinical Pharmacy and Pharmaceutical Economics & Policy, University of Southern California, School of Pharmacy, 1985 Zonal Avenue, Los Angeles, CA 90033, USA. susiepar@usc.edu
Current Drug Safety
|August 7, 2013
Summary
Antidepressant medications can cause liver injury (hepatotoxicity), ranging from reversible damage to fatal outcomes. Early detection through liver function monitoring and prompt drug discontinuation is crucial for patient safety.
Area of Science:
- Pharmacology
- Hepatology
- Psychiatry
Background:
- Antidepressants are widely used for depression and anxiety disorders.
- Adverse drug reactions, including hepatotoxicity, can occur even at therapeutic doses.
- Hepatotoxicity presents a significant safety concern in antidepressant pharmacotherapy.
Purpose of the Study:
- To review antidepressant-associated hepatotoxicity.
- To highlight the spectrum of liver injury caused by various antidepressants.
- To emphasize the importance of monitoring and early intervention.
Main Methods:
- Review of patient cases and literature on antidepressant-induced liver injury.
- Analysis of specific antidepressants linked to hepatotoxicity.
- Discussion of risk factors, including drug interactions and pre-existing liver conditions.
Main Results:
- Certain antidepressants (paroxetine, fluoxetine, etc.) are associated with reversible liver injury.
- Other antidepressants (nefazodone, trazodone, etc.) have been linked to fatal hepatotoxicity.
- Antidepressant-induced liver injury can occur within days to years and may be independent of risk factors like hepatitis.
Conclusions:
- Antidepressant-induced hepatotoxicity is an idiosyncratic reaction requiring vigilant monitoring.
- Early detection of liver dysfunction and prompt discontinuation of the offending agent are key to reversibility.
- Understanding these risks is essential for optimizing antidepressant treatment outcomes and patient safety.
Related Concept Videos
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...